Brazil’s Health Authority requires Registration Holders to send daily information to ANVISA regarding drugs necessary in COVID-19 Pandemic

ANVISA, blogs, Brazil, commercial, COVID-19, drug, importation, Latin America, public health emergency, Regulatory / By

Companies that hold drug registrations must provide Anvisa daily information about the manufacture, import and distribution of anesthetics, sedatives, neuromuscular blockers and adjuvant agents, among other drugs used to maintain the lives of patients infected with the new coronavirus (Sars-CoV-2).

China’s NMPA introduces new guidance for COVID-19 drug clinical trials

Asia, China, clinical, Clinical Services, clinical trials, Contract Research Organization (CRO), COVID-19, Guidances, infection control, Institutional Review Board (IRB) approval, Local Representation, National Medical Products Administration (NMPA), News, public health emergency, Regulatory Strategy, regulatory support, virus outbreak / By

China’s National Medical Product Administration (NMPA) released on July 2020 a guideline focused on the emergency approval of the new COVID-19 virus drugs and vaccines for sponsors and researchers.

Useful Links

Resources

Sign up for our Newsletter

What our Clients say about Us

Thank you GRP team for registering our DMF in china. Your helped us achieve a big milestone for our company. The support and the commitment of your regulatory team have exceeded our expectations and made it easier for us to communicate with NMPA the Chinese authority. All the best !
Director of Regulatory Affairs Officer- CMC- A Large European Pharmaceutical Company based in Switzerland
We have been working with Global Regulatory Partners for 5 years and we consider them as our real partner and not as a consulting company, they had submitted 3 INDs for us with FDA successfully . The GRP team performs all IND amendments and annual reporting to FDA, we don’t have to worry about not being in compliance with FDA requirements at all.
CEO of Medium Size American Pharmaceutical Company operating in Nanotechnology based in USA
After submitting our drug application to NPMA ( Chinese FDA) , the Chinese agency requested us to conduct a local clinical study. Finding the qualified CRO for the study management in china was very challenging process because of the language barrier and the lack of understanding of GCP and ICH requirements. We finally found Global Regulatory Partners, that has a local team of professionals in regulatory and clinical affairs in china who not only conducted successfully our clinical study in china, but also helped us to understand the Chinese regulations related to our product.
CMO of Large European Pharmaceutical Company based in France and Operating in Radiopharmaceuticals
I am very impressed on how quickly Global Regulatory Affairs team was able to prepare and organize a face to face consultation meeting for our company with Anvisa in Brazil, The meeting was successful and helped us to validate and conform the regulatory strategy of our device registration in Brazil.
VP of Global Regulatory Affairs, American Based Medical device Company

Copyright ©2019 Global Regulatory Partners

Scroll to Top

Contact